Search results for "Genetics"

showing 10 items of 12494 documents

The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes.

1998

The disappointing clinical results of cancer immunotherapy of the past few decades have not diminished the optimism about the potential of the new generation of immunotherapeutic strategies towards treatment of malignant disease. Tremendous progress has been made over recent years in unveiling the molecular basis of antigen presentation and recognition by cytotoxic T lymphocytes (CTL). The molecular concepts that have emerged from these studies have led to the design of novel anticancer vaccines and CTL-based immunotherapeutics. This review is to highlight the current molecular insights of antigen presentation and CTL recognition/activation, and their impact on the rational design of therap…

medicine.medical_treatmentAntigen presentationMolecular Sequence Datachemical and pharmacologic phenomenaCancer VaccinesImmune systemCancer immunotherapyNeoplasmsDrug DiscoverymedicineCytotoxic T cellAnimalsHumansAmino Acid SequenceGenetics (clinical)Antigen Presentationbusiness.industryImmunotherapyT lymphocyteMolecular medicineCTL*ImmunologyMolecular MedicineImmunotherapybusinessT-Lymphocytes CytotoxicJournal of molecular medicine (Berlin, Germany)
researchProduct

Gene expression centroids that link with low intrinsic aerobic exercise capacity and complex disease risk

2010

A strong link exists between low aerobic exercise capacity and complex metabolic diseases. To probe this linkage, we utilized rat models of low and high intrinsic aerobic endurance running capacity that differ also in the risk for metabolic syndrome. We investigated in skeletal muscle gene-phenotype relationships that connect aerobic endurance capacity with metabolic disease risk factors. The study compared 12 high capacity runners (HCRs) and 12 low capacity runners (LCRs) from generation 18 of selection that differed by 615% for maximal treadmill endurance running capacity. On average, LCRs were heavier and had increased blood glucose, insulin, and triglycerides compared with HCRs. HCRs we…

medicine.medical_treatmentBiochemistryResearch Communicationschemistry.chemical_compound0302 clinical medicineRisk Factorslipid metabolismOligonucleotide Array Sequence Analysis0303 health sciencesExercise ToleranceImmunohistochemistryMitochondriamedicine.anatomical_structureFemaleBiotechnologymedicine.medical_specialtyOxidative phosphorylationBiology03 medical and health sciencesOxygen ConsumptionMetabolic DiseasesPhysical Conditioning AnimalInternal medicineGeneticsmedicineAnimalsoxygen metabolismAerobic exerciseGenetic Predisposition to Diseaseskeletal muscleMuscle SkeletalMolecular BiologyAerobic capacity030304 developmental biologyMyosin Heavy Chainscomplex metabolic diseaseFatty acid metabolismGene Expression ProfilingInsulinSkeletal musclemedicine.diseaseRatsDisease Models AnimalEndocrinologyGene Expression RegulationchemistryBasal metabolic rateMetabolic syndromeEnergy Metabolism030217 neurology & neurosurgeryThe FASEB Journal
researchProduct

Clinical implications ofCYP3Apolymorphisms

2006

Due to their enormous substrate spectrum CYP3A4, -3A5 and -3A7 constitute the most important drug-metabolising enzyme subfamily in humans. CYP3As are expressed predominantly, but not exclusively, in the liver and intestine, where they participate in the metabolism of 45 - 60% of currently used drugs and many other compounds such as steroids and carcinogens. CYP3A expression and activity vary interindividually due to a combination of genetic and nongenetic factors such as hormone and health status, and the impact of environmental stimuli. Over the past several years, genetic determinants have been identified for much of the variable expression of CYP3A5 and -3A7, but not for CYP3A4. Using th…

medicine.medical_treatmentBiologyToxicologyBioinformatics030226 pharmacology & pharmacyGene Expression Regulation EnzymologicTacrolimusVariable Expression03 medical and health sciencesProstate cancer0302 clinical medicinemedicineCytochrome P-450 CYP3AHumansCYP3A5PharmacologyRegulation of gene expressionGeneticsPolymorphism GeneticCYP3A4General Medicinemedicine.diseaseTacrolimus3. Good healthIsoenzymesImmunosuppressive drug030220 oncology & carcinogenesisCyclosporineImmunosuppressive AgentsPharmacogeneticsExpert Opinion on Drug Metabolism & Toxicology
researchProduct

Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells

2013

Molecular targeted therapy has shown promise as a treatment for advanced hepatocellular carcinoma (HCC). Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of advanced HCC. However, although sorafenib is well tolerated, concern for its safety has been expressed. Celecoxib (Celebrex®) is a selective cyclooxygenase-2 (COX-2) inhibitor which exhibits antitumor effects in human HCC cells. The present study examined the interaction between celecoxib and sorafenib in two human liver tumor cell lines HepG2 and Huh7. Our data showed that each inhibitor alone reduced cell growth and the combination of celecoxib with sorafenib synergistically inhibited cell growth an…

medicine.medical_treatmentCancer TreatmentGene ExpressionApoptosisPharmacologyBiochemistryTargeted therapy0302 clinical medicineMolecular Cell Biology0303 health sciencesSulfonamidesMultidisciplinaryReverse Transcriptase Polymerase Chain ReactionQLiver NeoplasmsRDrug SynergismGenomicsSorafenib3. Good healthGene Expression Regulation NeoplasticOncology030220 oncology & carcinogenesisMedicineLiver cancermedicine.drugResearch ArticleBiotechnologySignal TransductionSorafenibNiacinamideProgrammed cell deathCarcinoma HepatocellularScienceBlotting WesternBiologyMolecular Genetics03 medical and health sciencesCell Line TumorGastrointestinal TumorsmedicineIn Situ Nick-End LabelingHumansneoplasmsBiology030304 developmental biologyCell ProliferationDNA PrimersHuman liver cancer Apoptosis Sorafenib Celecoxib anti-proliferative effectsCell growthGene Expression ProfilingPhenylurea CompoundsComputational BiologyCancers and NeoplasmsHepatocellular CarcinomaChemotherapy and Drug Treatmentmedicine.diseaseMicroarray Analysisdigestive system diseasesGene expression profilingApoptosisCell cultureCelecoxibPyrazolesGenome Expression AnalysisPLoS ONE
researchProduct

Lovastatin stimulates p75 TNF receptor (TNFR2) expression in primary human endothelial cells

2005

HMG-CoA reductase inhibitors (statins) exert pleiotropic physiological effects. Among others they attenuate cellular responses to genotoxic and inflammatory stress. We investigated the effect of lovastatin on the expression level of TNF receptors (TNFR) in primary human endothelial cells (HUVEC). ELISA, FACS and immunocytochemical analyses show that lovastatin selectively increases the cell surface expression of TNFR2 without affecting the expression level of TNFR1. This effect of lovastatin is independent from inhibition of cell-cycle progression since cells both in G1- and G2-phase showed elevated levels of TNFR2 after lovastatin treatment. To analyze the physiological relevance of lovast…

medicine.medical_treatmentCellBiologyDownregulation and upregulationE-selectinpolycyclic compoundsGeneticsmedicineHumansReceptors Tumor Necrosis Factor Type IILovastatinReceptorCells CulturedCell adhesion moleculeCell CycleEndothelial Cellsnutritional and metabolic diseasesGeneral MedicineFlow CytometryUp-RegulationCell biologymedicine.anatomical_structureCytokineReceptors Tumor Necrosis Factor Type ICancer researchbiology.proteinlipids (amino acids peptides and proteins)Tumor necrosis factor alphaLovastatinE-Selectinmedicine.drugInternational Journal of Molecular Medicine
researchProduct

Optimized culture conditions for tissue explants of uterine leiomyoma

2012

Background Uterine leiomyomas are the most common benign tumours in women, which arise from smooth muscle cells of the uterine myometrium and usually are multicentric. In spite of their frequency pathogenesis is widely unknown, mainly due to the absence of a suitable model system. We describe the systematic optimization of culturing leiomyoma tissue explants in an economical and effective ex vivo system. Methods Different concentrations of oxygen, different media, sera, hormones, and growth factor supplements were tested. Immunohistochemical stainings with antibodies against hormone receptors as well as specifying proliferation and apoptotic indices and real-time PCR were performed. Results…

medicine.medical_treatmentCulture Media; Epidermal Growth Factor; Estradiol; Female; Humans; Immunohistochemistry; Leiomyoma; Progesterone; RNA Messenger; Real-Time Polymerase Chain Reaction; Uterine NeoplasmsBiologyReal-Time Polymerase Chain ReactionGeneral Biochemistry Genetics and Molecular BiologyAndrologyTissue culturemedicineHumansRNA MessengerUterine NeoplasmProgesteroneUterine leiomyomaEpidermal Growth FactorEstradiolLeiomyomaGrowth factorMyometriummedicine.diseaseImmunohistochemistrySettore MED/40 - Ginecologia E OstetriciaCulture MediaLeiomyomaHormone receptorUterine NeoplasmsFemaleEx vivoHuman
researchProduct

Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man.

2002

Mutations and aberrant expression of the p53 tumor suppressor protein are the most frequent molecular alterations in human malignancy. Peptides derived from the wild-type (wt) p53 protein and presented by major histocompatibility complex (MHC) molecules for T lymphocyte recognition are believed to serve as universal tumor-associated antigens for cancer immunotherapy. We studied the immunogeneicity of a recombinant replication-defective adenoviral vector encoding human full-length wt p53 (rAd/hup53) in human leukocyte antigen (HLA)-A2K(b)-transgenic (Tg) mice and man. The generation of p53 epitope-specific cytotoxic T lymphocytes (CTLs) in p53-proficient and p53-deficient A2K(b)-Tg mice was …

medicine.medical_treatmentGenetic VectorsEpitopes T-LymphocyteMice TransgenicPilot ProjectsHuman leukocyte antigenBiologyMajor histocompatibility complexCancer VaccinesEpitopeAdenoviridaeMiceImmune systemCancer immunotherapyAntigenSpecies SpecificityNeoplasmsHLA-A2 AntigenGeneticsmedicineCytotoxic T cellAnimalsHumansTreatment FailureMolecular BiologyT lymphocyteGenetic TherapyGenes p53Self ToleranceImmunologybiology.proteinMolecular MedicineTumor Suppressor Protein p53T-Lymphocytes CytotoxicGene therapy
researchProduct

More about genetically modified tumour vaccines

1998

medicine.medical_treatmentGenetic enhancementGene Transfer TechniquesMEDLINEImmunotherapy ActiveGenetic TherapyImmunotherapyBiologyCancer VaccinesGenetically modified organismGeneticsmedicineCancer researchCytokinesHumansMolecular MedicineMolecular BiologyGene Therapy
researchProduct

Effects of Th1 and Th2 cytokines on cytokine production and ICAM-1 expression on synovial fibroblasts

1995

OBJECTIVES--To investigate the influence of the Th1 and Th2 lymphokines interleukins (IL)-4 and IL-13, interferon gamma (IFN gamma), and several monokines on the adhesion of mononuclear cells to synovial fibroblasts and intercellular adhesion molecule-1 (ICAM-1) expression and cytokine production of synovial fibroblasts in patients with osteoarthritis. METHODS--Synovial fibroblasts were isolated from patients with osteoarthritis and stimulated with IL-1 beta, IL-4, IL-6, IL-10, IL-12, IL-13, tumour necrosis factor alpha (TNF alpha), and IFN gamma. Subsequently, we determined the production of IL-1 alpha, IL-1 beta, IL-6, IL-10, IL-12, IFN alpha and TNF alpha, and the expression of ICAM-1 ly…

medicine.medical_treatmentImmunologyIntercellular Adhesion Molecule-1BiologyGeneral Biochemistry Genetics and Molecular BiologyTh2 CellsRheumatologyOsteoarthritisCell AdhesionmedicineHumansImmunology and AllergyInterferon gammaCell adhesionCells CulturedInterleukin-13Interleukin-6Cell adhesion moleculeSynovial MembraneLymphokineReceptors InterleukinFibroblastsTh1 CellsIntercellular Adhesion Molecule-1Molecular biologyRecombinant ProteinsReceptors Interleukin-4Cytokinemedicine.anatomical_structureImmunologyCytokinesTumor necrosis factor alphaInterleukin-4Synovial membraneResearch Articlemedicine.drug
researchProduct

Growth factors and cell kinetics: a mathematical model applied to Il-3 deprivation on leukemic cell lines.

1992

We assume the existence of a specific G1 protein which is an initiator of DNA replication. This initiator is supposed to be synthesized according to Michaelis-Menten kinetics. In order to start DNA replication, it is assumed that this G1 specific protein must be produced in a required amount. Intra-cellular growth inhibitors and extra-cellular growth factors control the production of the initiator. This model allows to calculate the average G1 phase time as a function of the various chemical concentrations of nutrients, enzymes, growth inhibitors and growth factors. This model is compared to cell kinetics experiments on a leukemic cell line responding to Interleukin 3 deprivation. The curve…

medicine.medical_treatmentKineticsBiologyModels BiologicalGeneral Biochemistry Genetics and Molecular BiologymedicineCells CulturedGeneral Environmental ScienceInterleukin 3chemistry.chemical_classificationLeukemia ExperimentalApplied MathematicsGrowth factorDNA replicationG1 PhaseGeneral MedicineDNACell cyclePhilosophyKineticsEnzymeCytokineBiochemistrychemistryCell cultureBiophysicsInterleukin-3General Agricultural and Biological SciencesActa biotheoretica
researchProduct